Loading…
Xenetic Biosciences, Inc. is projected to rise to $3.19 by 2027, a +20% move from its current price of $2.66. XBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.59 | $2.66 | $2.73 | +0.01% |
| Aug 6 | $2.56 | $2.66 | $2.76 | +0.01% |
| Aug 7 | $2.54 | $2.66 | $2.78 | +0.02% |
| Aug 8 | $2.53 | $2.66 | $2.80 | +0.02% |
| Aug 9 | $2.51 | $2.66 | $2.82 | +0.03% |
| Aug 10 | $2.50 | $2.66 | $2.84 | +0.04% |
| Aug 11 | $2.48 | $2.66 | $2.85 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.48 | $2.66 | $2.85 | +0.04% |
| Week 2 | $2.41 | $2.66 | $2.94 | +0.08% |
| Week 3 | $2.36 | $2.66 | $3.00 | +0.12% |
| Week 4 | $2.32 | $2.66 | $3.06 | +0.16% |
| Week 5 | $2.28 | $2.67 | $3.11 | +0.20% |
| Week 6 | $2.25 | $2.67 | $3.16 | +0.25% |
| Week 7 | $2.22 | $2.67 | $3.20 | +0.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC.
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Xenetic Biosciences, Inc. trades under the symbol XBIO. The current price is $2.50, and the market cap is $5.73M. It is ranked 5058. The stock operates in the Healthcare sector. The price outlook is elevated over the longer term, with a sequence of forecasts showing growth from 2026 onward; the 2026 average price is $2.50, rising through 2027 to $3.03, 2028 to $3.30, and 2029 to $3.51, culminating in a 2030 average of $3.55.
The forecast continues with gains through 2040 (avg $6.00) and 2050 (avg $11.37), with maximums reaching as high as $22.01 by 2050. The outlook reflects bullish sentiment from 2027 onward and a rising return profile, with ROI values climbing from 0 in 2026 to 21.3 in 2027 and up to 354.9 by 2050.
A major floor 19.1% below — a decisive break under it would weaken the trend.
The nearest floor, 6.8% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 33.8% above — clearing it would confirm fresh momentum.
Key XBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.51 | Buy | $2.55 | Buy |
| MA 10 | $2.61 | Buy | $2.60 | Buy |
| MA 20 | $2.72 | Sell | $2.69 | Sell |
| MA 50 | $2.91 | Sell | $2.83 | Sell |
| MA 100 | $2.98 | Sell | $2.87 | Sell |
| MA 200 | $2.79 | Sell | $2.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.16 | Neutral |
| Stoch RSI (14) | 21.32 | Neutral |
| CCI (20) | -101.08 | Sell |
| Williams %R (14) | -89.42 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -12.59 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 10.58 | Buy |
| TRIX (15) | -0.47 | Sell |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 31.20 | Neutral |
| Momentum (10) | -0.25 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 2.48 | Buy |
| ADX (14) | 17.17 | Neutral |
| ATR (14) | 0.07 | Info |
The near-term picture is Neutral. The RSI14 is 40, and the stock’s SMA50 is $2.96 while the SMA200 is $2.90. Near-term support stands at $2.50 and resistance at $3.24. The 30-day price range runs from a low of $2.04 to a high of $3.06. The stock also exhibits an annualized volatility of 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.08 | $2.66 | $3.40 | 0% | Neutral | |
| $2.56 | $3.19 | $4.21 | +20% | Bullish | |
| $2.72 | $3.49 | $4.76 | +31% | Bullish | |
| $2.85 | $3.74 | $5.25 | +40% | Bullish | |
| $2.82 | $3.77 | $5.42 | +42% | Bullish | |
| $2.79 | $3.80 | $5.58 | +43% | Bullish | |
| $2.80 | $3.87 | $5.79 | +46% | Bullish | |
| $2.88 | $4.05 | $6.16 | +52% | Bullish | |
| $3.59 | $5.11 | $7.90 | +92% | Bullish | |
| $3.84 | $5.55 | $8.71 | +109% | Bullish | |
| $4.35 | $6.70 | $11.15 | +152% | Bullish | |
| $7.39 | $12.69 | $23.06 | +377% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.08 | $2.66 | $3.17 | +0.00% |
| September 2026 | $2.20 | $2.60 | $3.15 | -2.26% |
| October 2026 | $2.25 | $2.67 | $3.28 | +2.86% |
| November 2026 | $2.32 | $2.77 | $3.42 | +3.59% |
| December 2026 | $2.27 | $2.73 | $3.40 | -1.49% |
Click any year to see its month-by-month XBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The XBIO price prediction for 2026 points to an average of $2.66 (low $2.08, high $3.40) — a potential gain of 0% on today's $2.66. A consolidation phase looks the most probable path here.
In 2027, XBIO is projected to trade between $2.56 and $4.21, averaging $3.19 — a potential gain of +20% from today's $2.66. That is up +20% on the projected 2026 average. Momentum favours further upside here.
Xenetic Biosciences, Inc.'s 2028 outlook centres on $3.49, within a $2.72 to $4.76 range. That is up +9% on the projected 2027 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, XBIO could reach as high as $5.25, with a base case around $3.74 and support toward $2.85 — roughly +40% from $2.66. Momentum favours further upside here.
Expect XBIO to range from $2.82 to $5.42 through 2030. The $3.77 average target implies a +42% move from current prices. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The XBIO price prediction for 2031 points to an average of $3.80 (low $2.79, high $5.58) — a potential gain of +43% on today's $2.66. Momentum favours further upside here.
In 2032, XBIO is projected to trade between $2.80 and $5.79, averaging $3.87 — a potential gain of +46% from today's $2.66. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Xenetic Biosciences, Inc.'s 2033 outlook centres on $4.05, within a $2.88 to $6.16 range. That is up +5% on the projected 2032 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2034, XBIO could reach as high as $7.90, with a base case around $5.11 and support toward $3.59 — roughly +92% from $2.66. Buyers look set to stay in control over this stretch.
Expect XBIO to range from $3.84 to $8.71 through 2035. The $5.55 average target implies a +109% move from current prices. That is up +9% on the projected 2034 average. Momentum favours further upside here.
The XBIO price prediction for 2040 points to an average of $6.70 (low $4.35, high $11.15) — a potential gain of +152% on today's $2.66. Buyers look set to stay in control over this stretch.
In 2050, XBIO is projected to trade between $7.39 and $23.06, averaging $12.69 — a potential gain of +377% from today's $2.66. That is up +90% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XBIO today (≈ 375.93985 XBIO) could be worth
$4,771.1
+$3,771.1 (+377%) by 2050 · US Dollar
Based on the average projected XBIO price of $12.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XBIOwould be worth at today's price.
$1,000 invested in XBIO on Jul 31, 2025 (≈ 308.641974 XBIO) would be worth
$820.99
-$179.01 (-17.9%) today · 0.82× · US Dollar
Based on a XBIO entry price of $3.24 vs. today's $2.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.64 | $1,007.58 | +0.8% |
| 1 month ago | $2.94 | $904.76 | -9.5% |
| 3 months ago | $2.97 | $895.62 | -10.4% |
| 6 months ago | $2.25 | $1,182.22 | +18.2% |
| 1 year ago | $3.24 | $820.99 | -17.9% |
| All time (5.0y) ago | $35.8 | $74.3 | -92.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XBIO forecast.
Our base-case forecast reaches $5.30 around 2035.
Implied market cap at $5.30: $12.14M
The multi-year forecast shows a bullish trajectory, with the average price progressing from $2.50 in 2026 to $3.55 in 2030, and then higher in later years. By 2030, the avg is $3.55 with an ROI of 42 and sentiment bullish. The outlook strengthens further toward 2040 with an avg of $6.00 and ROI of 140.1, and by 2050 the avg is $11.37 with ROI of 354.9, accompanied by bullish sentiment.
The max forecasted prices rise to $5.29 in 2030, $10.54 in 2040, and $22.01 in 2050, with corresponding min values of $2.58, $3.66, and $6.04 respectively. The path implies meaningful upside over the period, but it remains subject to risk and uncertainty, including market volatility (60% annualized).
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $3.55, a min of $2.58, a max of $5.29, and an ROI of 42, with sentiment BULLISH.
The outlook is bullish from 2027 onward, with 2027 avg $3.03, 2028 avg $3.30, 2029 avg $3.51, and 2030 avg $3.55. ROI progresses to 21.3 in 2027 and to 42 by 2030, continuing higher through 2050 (354.9).
Yes. The 2030 max forecast is $5.29, indicating a potential to exceed $5 within that year.
The current price is $2.50 and the annualized volatility is 60%.
For 2040, the avg is $6.00 with a max of $10.54 and a min of $3.66 (ROI 140.1). For 2050, the avg is $11.37 with a max of $22.01 and a min of $6.04 (ROI 354.9). The sentiment remains BULLISH.
Xenetic Biosciences, Inc. Community Discussion
0Share your Xenetic Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.